Quick Answer
DNA X, Inc. reported Cash and Equivalents of $5.34 million for fiscal year 2024.
DNA X, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $5.34M | -43.1% |
| 2023 | $9.40M | -28.9% |
| 2022 | $13.21M | +17.6% |
| 2021 | $11.23M | -49.3% |
| 2020 | $22.14M | +96.0% |
| 2019 | $11.30M | -13.4% |
| 2018 | $13.05M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.14M | -76.4% | +6.5% |
| June 30, 2025 | $2.01M | -79.1% | -5.2% |
| March 31, 2025 | $2.12M | -77.1% | -60.4% |
| December 31, 2024 | $5.34M | -43.1% | -41.0% |
| September 30, 2024 | $9.06M | -7.5% | -5.6% |
| June 30, 2024 | $9.60M | -1.2% | +3.8% |
| March 31, 2024 | $9.25M | +3.3% | -1.5% |
| December 31, 2023 | $9.40M | -28.9% | -4.1% |
- DNA X, Inc. showed a decrease of -43.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2024 period, DNA X, Inc.’s cash and equivalents has declined by 59.1% (from $13.05 million to $5.34 million).
- The most recent figure is from DNA X, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: